ClinicalTrials.gg
CompletedNCT01266876Updated Sep 22, 2015Results posted

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

A Phase 2 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 22 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-22.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
27th of 43
77 · median 107
Started
2011
with 6 others
Phase 2
9 of 43
none open now
Registered
2nd of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 27th largest by enrollment, is one of 7 that started in 2011, is one of 9 in phase 2, and was the 2nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Must meet the World Health Organization criteria for heFH
  2. Participants must be on a stable statin dose, with or without ezetimibe, for at least 6 weeks before screening
  3. Serum LDL-C levels ≥ 100 mg/dL at screening
  4. Willing to follow the NCEP ATPIII TLC diet, or an equivalent diet plan, starting at screening and continuing until the last study visit
  5. A negative urine/serum pregnancy test at each screening visit and start of the study, for women of

Key Exclusion Criteria:

  1. Participants with homozygous FH (clinically or by previous genotyping)
  2. Use of a medication (other than a statin or EZE) to alter serum lipids within 42 days (6 weeks) before screening including, but not limited to:

    • Fibrates
    • Niacin (>500 mg/day)
    • Omega-3 fatty acids (>1000 mg/day of DHA/EPA)
    • Bile acid resins
  3. Use of nutraceuticals or OTC medications that may alter lipid levels that are not stable for at least 6 weeks before screening and are not planned to remain constant throughout the study. Examples include:

    • Omega-3 fatty acids (≤1000 mg/day of DHA/EPA)
    • Niacin (≤500 mg/day)
    • Plant stanols, such as found in Benecol, flax seed oil, psyllium
    • Red yeast rice
  4. Disorders known to influence lipid levels, such as nephrotic syndrome, significant liver disease, Cushing's disease, untreated hypothyroidism (patients on stable thyroid replacement for at least 12 weeks before the full screening visit, who are metabolically euthyroid by thyroid-stimulating hormone (TSH) testing are allowed)
  5. Use of thyroid medications (except for replacement therapy which has been stable for at least 12 weeks before the full screening visit)
  6. Fasting serum TG >350 mg/dL screening
  7. LDL apheresis within 12 months before screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.

    Drug: Placebo

  • Experimental
    Alirocumab 150 mg Q4W

    Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.

    Drug: Alirocumab

  • Experimental
    Alirocumab 200 mg Q4W

    Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.

    Drug: Alirocumab

  • Experimental
    Alirocumab 300 mg Q4W

    Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.

    Drug: Alirocumab

  • Experimental
    Alirocumab 150 mg Q2W

    Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.

    Drug: Alirocumab

Interventions

  • Alirocumab two SC injections in the abdomen only.

    Also known as: REGN727/SAR236553

  • DrugPlacebo

    Placebo two SC injections in the abdomen only.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

    Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational medicinal product (IMP) injection up to 21 days after last IMP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

    Time frame: From Baseline to Week 12 (LOCF)

Secondary outcomes

  1. Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

    Calculated LDL-C value was obtained from Friedewald formula. Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  2. Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis

    Calculated LDL-C value was obtained from Friedewald formula.

    Time frame: Week 12 (LOCF)

  3. Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis

    Calculated LDL-C value was obtained from Friedewald formula.

    Time frame: Week 12 (LOCF)

  4. Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  5. Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  6. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint..

    Time frame: From Baseline to Week 12 (LOCF)

  7. Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  8. Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)

    Time frame: From Baseline to Week 12 (LOCF)

  9. Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)

    Time frame: From Baseline to Week 12 (LOCF)

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12

  11. Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  12. Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  13. Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12

  14. Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  15. Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12 (LOCF)

  16. Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis

    Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

    Time frame: From Baseline to Week 12

  17. Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)

    Time frame: From Baseline to Week 12 (LOCF)

  18. Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis

    Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)

    Time frame: From Baseline to Week 12 (LOCF)

07

Results

Posted Sep 22, 2015

Participant flow

The study was conducted at 16 centers in the United States of America and Canada. Overall, 118 participants were screened between January 2011 and June 2011.

Participant flow — Overall Study
MilestonePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Started1515161516
Completed1515161416
Not completed00010
Withdrew: Adverse event00010

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

Calculated LDL-C values were obtained using the Friedewald formula. Baseline adjusted least squares (LS) means and standard errors were estimated using an analysis of covariance (ANCOVA) model including available post-baseline data on treatment from first investigational medicinal product (IMP) injection up to 21 days after last IMP injection (on-treatment analysis). Missing Week 12 data were imputed by last observation carried forward \[LOCF\] method.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis-10.7 ± 5.0-28.9 ± 5.1-31.5 ± 4.9-42.5 ± 5.1-67.9 ± 4.9
Statistical analysis
  • Placebo vs Alirocumab 150 mg Q2W · ANCOVA · p = 0.0000 (Threshold for significance at ≤ 0.05.)
  • Placebo vs Alirocumab 300 mg Q4W · ANCOVA · p = 0.0000 (Threshold for significance at ≤ 0.05.)
  • Placebo vs Alirocumab 200 mg Q4W · ANCOVA · p = 0.0035 (Threshold for significance at ≤ 0.05.)
  • Placebo vs Alirocumab 150 mg Q4W · ANCOVA · p = 0.0113 (Threshold for significance at ≤ 0.05.)
SecondaryAbsolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis

Calculated LDL-C value was obtained from Friedewald formula. Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis-19.1 ± 7.9-42.2 ± 8.0-51.3 ± 7.7-66.9 ± 8.0-102.5 ± 7.6
SecondaryPercentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis

Calculated LDL-C value was obtained from Friedewald formula.

Time frame:
Week 12 (LOCF)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis
percentage of participantsPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis13.326.718.866.793.8
SecondaryPercentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis

Calculated LDL-C value was obtained from Friedewald formula.

Time frame:
Week 12 (LOCF)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis
percentage of participantsPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis0.013.312.546.781.3
SecondaryPercent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis-8.5 ± 3.8-18.1 ± 3.9-19.7 ± 3.7-25.7 ± 3.8-43.6 ± 3.7
SecondaryAbsolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis-20.3 ± 9.4-40.3 ± 9.5-50.1 ± 9.2-61.7 ± 9.5-99.9 ± 9.1
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint..

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis2.2 ± 3.77.9 ± 3.76.5 ± 3.51.00 ± 3.812.3 ± 3.6
SecondaryAbsolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis0.4 ± 1.94.2 ± 1.93.3 ± 1.84.5 ± 2.06.0 ± 1.8
SecondaryPercent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Median · percent change
Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis-10.6 (-28.5 to 9.5)-16.7 (-30.1 to 21.1)-13.2 (-30.9 to 7.4)-4.9 (-17.0 to 10.3)-16.2 (-30.7 to 25.1)
SecondaryAbsolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Median · mg/dL
Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis-11.0 (-89.5 to 7.5)-20.0 (-37.0 to 13.0)-13.5 (-35.3 to 9.5)-3.5 (-33.0 to 6.0)-14.8 (-64.5 to 34.0)
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis-11.3 ± 4.7-26.8 ± 4.8-27.4 ± 4.6-39.0 ± 4.8-57.9 ± 4.6
SecondaryAbsolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis-22.8 ± 8.8-46.0 ± 8.9-52.3 ± 8.6-70.6 ± 9.0-103.6 ± 8.5
SecondaryPercent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis-6.4 ± 4.2-20.9 ± 4.2-20.9 ± 4.0-28.4 ± 4.3-50.2 ± 4.0
SecondaryAbsolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis-9.3 ± 5.5-24.3 ± 5.5-28.7 ± 5.3-34.7 ± 5.6-64.4 ± 5.3
SecondaryPercent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis-5.3 ± 3.12.4 ± 3.11.7 ± 2.95.6 ± 3.18.8 ± 2.9
SecondaryAbsolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Least squares mean · mg/dL
Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis-9.7 ± 4.63.4 ± 4.52.8 ± 4.37.8 ± 4.611.0 ± 4.4
SecondaryAbsolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis

Adjusted LS means and standard errors were estimated using the same ANCOVA model as for primary endpoint.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · ratio
Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis
ratioPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis-0.03 ± 0.04-0.18 ± 0.04-0.20 ± 0.04-0.25 ± 0.04-0.49 ± 0.04
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameters, percent changes were expressed as median (interquartile range)

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Median · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis
percent changePlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis-3.9 (-18.4 to 0.0)-10.1 (-22.2 to 3.8)-7.5 (-22.5 to 0.0)-15.3 (-25.2 to 10.6)-23.4 (-44.6 to -6.6)
SecondaryAbsolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis

Since the assumptions of normal distribution and equality of variances were not verified for the lipid parameter, percent changes were expressed as median (interquartile range)

Time frame:
From Baseline to Week 12 (LOCF)
Reported as:
Median · mg/dL
Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis
mg/dLPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis-2.0 (-7.0 to 0.0)-1.5 (-10.0 to 1.5)-1.8 (-5.0 to 0.0)-8.0 (-19.0 to 5.0)-11.5 (-26.0 to 1.8)

Adverse events

Collected over From Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/15 (6.7%)9/15 (60%)
Alirocumab 150 mg Q4W—0/15 (0%)12/15 (80%)
Alirocumab 200 mg Q4W—0/16 (0%)13/16 (81.3%)
Alirocumab 300 mg Q4W—0/15 (0%)13/15 (86.7%)
Alirocumab 150 mg Q2W—0/16 (0%)12/16 (75%)
Most frequent serious events
Most frequent serious events
EventPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Intestinal obstructionGastrointestinal disorders1/150/150/160/150/16
Most frequent other events
Showing 10 of 118
Most frequent other events
EventPlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2W
Injection site erythemaGeneral disorders0/152/154/164/150/16
DiarrhoeaGastrointestinal disorders0/153/153/161/150/16
Injection site haematomaGeneral disorders1/153/150/162/151/16
Injection site pruritusGeneral disorders0/150/150/163/150/16
FatigueGeneral disorders1/152/151/162/150/16
Injection site exfoliationGeneral disorders0/150/151/162/150/16
NasopharyngitisInfections and infestations2/150/152/161/150/16
SinusitisInfections and infestations0/152/150/161/150/16
Upper respiratory tract infectionInfections and infestations0/150/150/162/150/16
ArthralgiaMusculoskeletal and connective tissue disorders1/152/150/161/150/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2WTotal
Mean51.9 ± 9.651.3 ± 7.752.9 ± 11.254.3 ± 9.656.3 ± 10.253.4 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2WTotal
Female6678330
Male99971347
Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL
Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL(mg/dL)PlaceboAlirocumab 150 mg Q4WAlirocumab 200 mg Q4WAlirocumab 300 mg Q4WAlirocumab 150 mg Q2WTotal
Mean150.8 ± 34.0166.7 ± 50.1169.8 ± 57.0139.6 ± 24.7147.2 ± 32.6154.9 ± 42.1
08

Study locations

22 sites
  • Huntsville, Alabama, United States
  • Mission Viejo, California, United States
  • Newport Beach, California, United States
  • Bridgeport, Connecticut, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Port Orange, Florida, United States
  • Chicago, Illinois, United States
  • Kansas City, Kansas, United States
  • Auburn, Maine, United States
  • Biddeford, Maine, United States
  • St. Louis, Missouri, United States
  • Concord, New Hampshire, United States
  • Durham, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Winnipeg, Manitoba, Canada
  • London, Ontario, Canada
  • Chicoutimi, Quebec, Canada
  • Montreal, Quebec, Canada
  • St. Foy, Quebec, Canada
09

References and documents

Publications

  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia. J Clin Lipidol. 2017 Nov-Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4. Erratum In: J Clin Lipidol. 2020 Sep - Oct;14(5):742. doi: 10.1016/j.jacl.2020.09.010. PubMed 28964736 ↗
  • Toth PP, Hamon SC, Jones SR, Martin SS, Joshi PH, Kulkarni KR, Banerjee P, Hanotin C, Roth EM, McKenney JM. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis. 2016 Feb 13;15:28. doi: 10.1186/s12944-016-0197-4. PubMed 26872608 ↗
  • Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. doi: 10.1016/S0140-6736(12)60771-5. Epub 2012 May 26. PubMed 22633824 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 3 years 10 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2010
First posted
Dec 24, 2010
Start
Jan 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results delay requested
Apr 19, 2011
Results first posted
Sep 22, 2015
Last update
Sep 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01266876
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Dec 24, 2010
Start date
Jan 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Sep 22, 2015
Last update
Sep 22, 2015

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion